China Resources Double-Crane Pharmaceutical (Jinan) Co., Ltd.

The main purpose of the study is to study the pharmacokinetics of the test preparation Nicergoline Tablets (Specification: 30mg, produced by China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd.) and the reference preparation Nicergoline Tablets (Sermion®, Specification: 30mg, produced by Pfizer Italia S.r.l.) in healthy adult subjects after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation and reference preparation of Nicergoline Tablets after a single oral administration in healthy subjects in the fasting and fed state.

This study aimed to investigate the pharmacokinetic characteristics of a single fasting oral dose of bosentan dispersible tablets (32 mg) developed and produced by China Resources Double Crane Limin Pharmaceuticals (Jinan) Co., Ltd.; using bosentan dispersible tablets (Tracleer®, 32 mg) licensed by Actelion Pharmaceuticals Ltd and produced by Patheon Inc. as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.

The aim of this study was to investigate the pharmacokinetic characteristics of a single oral dose of the test preparation T Aluminum Magnesium Aspirin Tablets (II) (Specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, and 11 mg aluminum glycolate) provided by China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. and the reference preparation R Aluminum Magnesium Aspirin Tablets (II) (trade name: BUFFERIN Combination Tab. A81; Specification: each tablet contains 81 mg aspirin, 22 mg heavy magnesium carbonate, and 11 mg aluminum glycolate) certified by Lion Corporation in the fasting and fed state.